STOCK TITAN

Humacyte (HUMA) Stock News

HUMA NASDAQ

Humacyte, Inc. reports commercial, clinical and regulatory developments for its bioengineered human tissue platform. The company’s first FDA-approved product, Symvess, is an acellular tissue engineered vessel indicated for treatment of extremity vascular trauma, while other ATEV applications remain part of its broader regenerative medicine pipeline.

Recurring updates include Symvess commercialization, hospital access and distribution arrangements, international regulatory submissions, and clinical work in arteriovenous access for hemodialysis patients. Humacyte also reports quarterly financial results, business-development activity, financing actions and leadership changes tied to its transition from platform development to commercial-stage biotechnology operations.

Rhea-AI Summary

Humacyte (HUMA) submitted an FDA application to add hemodialysis access as a second approved use for its bioengineered blood vessel. The application covers patients with end-stage kidney disease at increased risk that an arteriovenous fistula will not develop enough to be used for dialysis. The FDA approved the vessel as Symvess in December 2024 for extremity vascular trauma.

Three Phase 3 studies support the application. Interim V012 results showed that women who received the vessel gained usable dialysis access more than three months sooner and spent more time without a dialysis catheter over the first year than women who received a fistula. The FDA has 60 days to assess whether the application is complete and acceptable for filing and to set a review timeline. Humacyte requested Priority Review.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Humacyte (HUMA) presented clinical findings showing low observed susceptibility to atherosclerosis, or artery plaque buildup, in its acellular tissue engineered vessel (ATEV).

The analysis covered tissue from 52 patients across five clinical trials involving hemodialysis access or peripheral artery bypass. Implant durations ranged from less than one week to more than five years. Lipid deposits averaged 0.6% of tissue area, with scarce foam cells, an early plaque indicator. Inflammatory cells were largely absent from vessel walls. Over 95% of evaluated explants showed no or only minor early atherosclerosis markers. Some atypical fatty streaks appeared in 4.7% of studied ATEVs, but none showed vulnerable plaques. The vessels progressively gained patients’ own cells and remodeled. Humacyte believes the findings support potential long-term durability; uses beyond the approved extremity vascular trauma indication remain investigational.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.24%
Tags
-
Rhea-AI Summary

Humacyte (HUMA) will feature its acellular tissue engineered vessel in five presentations at the VEITHsymposium on November 17–21, 2026.

Four presentations on November 18 will cover an infected-field reconstruction case, interim Phase 3 dialysis-access results in women, integrated outcomes from three Phase 3 trials and long-term explant evidence. A November 19 presentation will update Symvess clinical experience in military and civilian trauma settings. Humacyte plans to submit a supplemental biologics license application for arteriovenous access for hemodialysis in November. That use remains investigational.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
none
Rhea-AI Summary

Humacyte (Nasdaq: HUMA) reported third-quarter 2026 Symvess sales of $1.0 million, more than doubling the previous quarter as hospital adoption expanded. Sales rose 151% sequentially and compared with $0.7 million a year earlier. Hospitals ordering Symvess increased to 49 from 34 at the second-quarter end. October sales reached $0.8 million; Humacyte expects fourth-quarter sales to at least double third-quarter sales.

Quarterly net loss narrowed to $15.5 million from $17.5 million a year earlier. Operating cash use fell to $15.0 million from $23.9 million, with cash, cash equivalents and restricted cash of $64.9 million at September 30. Humacyte plans a November 2026 FDA application to add dialysis access as an approved use for its bioengineered vessel. It also initiated a Phase 2a study of its coronary tissue engineered vessel for coronary artery bypass grafting in November.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.61%
Tags
-
Rhea-AI Summary

Humacyte (HUMA) has initiated a first-in-human Phase 2a study of its bioengineered coronary vessel for coronary artery bypass surgery. The study is open for enrollment and will evaluate safety and efficacy in ten adults with coronary artery disease. Vessel patency, or whether the graft remains open, will be assessed two months after implantation, with follow-up for up to three years. The FDA accepted the investigational new drug application in July 2026.

Presentations at the American Heart Association Scientific Sessions 2026 included preclinical results showing implanted vessels remained open for up to three months in sheep, with host cells populating the vessel walls. The coronary vessel remains investigational and is not approved for sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
none
-
Rhea-AI Summary

Humacyte (Nasdaq: HUMA) will feature its regenerative medicine technology in three presentations at the American Heart Association Scientific Sessions 2026.

The conference runs November 6–9 at McCormick Place in Chicago. Founder and CEO Laura Niklason will give an invited talk on vascular regeneration on November 7. Two other presentations will cover the first-in-human Phase 2a study design and preclinical results in pig and sheep models for the company’s coronary tissue engineered vessel, intended for coronary artery bypass grafting. Those presentations are scheduled for November 7 and November 8, respectively. The coronary vessel remains investigational and is not approved for sale by the FDA or any other regulatory agency.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.65%
Tags
none
Rhea-AI Summary

Humacyte (HUMA) will release its third-quarter 2026 financial results and provide a business update on November 10, 2026. The results will cover the three months and nine months ended September 30, 2026. Management will host a webcast and conference call at 8:00 a.m. Eastern Time to discuss the corporate and financial update.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.19%
Tags
earnings date
-
Rhea-AI Summary

Humacyte (Nasdaq: HUMA) received a new U.S. patent covering aspects of Symvess manufacturing, sterilization, storage and shipping, with protection into 2043.

U.S. Patent No. 12,742,144 also covers other bioengineered human tissues and complements existing patents and applications covering product design, composition and manufacturing methods. Symvess is an acellular tissue engineered vessel, a bioengineered blood vessel, that received FDA approval for extremity vascular trauma in December 2024. Humacyte plans to submit a supplemental biologics license application in 2026 seeking to add dialysis access as a second approved indication.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.33%
Tags
none
-
Rhea-AI Summary

Humacyte (HUMA) reported that its Phase 3 V012 trial met the primary endpoint comparing bioengineered vessels with fistulas in female hemodialysis patients. The prespecified interim analysis covered the first 80 patients; enrollment stopped after the endpoint was met. Women receiving the acellular tissue engineered vessel (ATEV) averaged 220 catheter-free days in the first year, versus 129 with a surgically created arteriovenous fistula. Median time to functional dialysis access was 1.7 months versus 5.3 months.

Safety was comparable between groups. Dialysis access infections occurred at approximately 6 versus 23 per 100 patient-years, with no vessel-related infections in the ATEV group or spontaneous ruptures in either group. Humacyte targets an FDA application this quarter to expand the Symvess label to hemodialysis access, supported by V012 and two previously completed Phase 3 trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.40%
Tags
Rhea-AI Summary

Humacyte (HUMA) reported a 44% third-quarter increase in hospitals that have ordered Symvess, its FDA-approved vessel for vascular trauma. The total rose from 34 hospitals at the end of the second quarter to 49 as of September 30, 2026. New hospital ordering activity increased sequentially each month of the third quarter.

Humacyte said the adoption trend shows potential to surpass its goal of adding 20 new hospitals by year-end and expects substantial growth through the remainder of 2026. Its revised commercial strategy began in the second quarter. Symvess is approved for adults with extremity arterial injury who need urgent restoration of blood flow to avoid imminent limb loss and cannot receive a graft made from their own vein. Further commercial updates are planned for the third-quarter earnings call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.12%
Tags
none

FAQ

What is the current stock price of Humacyte (HUMA)?

Humacyte (HUMA) last closed at $0.5425.

What is the market cap of Humacyte (HUMA)?

The market cap of Humacyte (HUMA) is approximately $150.7M.